Vera Therapeutics (Nasdaq:VERA) - Cours de l'action, nouvelles et analyse

VERA Aperçu des actions

VERA analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	5/6
Dividendes	0/6

Récompenses

Se négocie à 88.7% en dessous de notre estimation de sa juste valeur

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

Vera Therapeutics, Inc. Concurrents

VitaSpring Biomedical

OTCPK:VSBC

US$3.1b

Dyne Therapeutics

NasdaqGS:DYN

US$3.1b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Xenon Pharmaceuticals

NasdaqGM:XENE

US$3.0b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Vera Therapeutics
Historique des cours de bourse
Prix actuel de l'action	US$47.03
Plus haut sur 52 semaines	US$51.61
Plus bas sur 52 semaines	US$12.28
Bêta	1.02
1Variation sur 1 mois	15.52%
Variation sur 3 mois	19.67%
Variation sur 1 an	257.37%
3Variation sur 3 ans	77.47%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	308.96%

Nouvelles et mises à jour récentes

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Rendement pour les actionnaires

	VERA	US Biotechs	US Marché
7D	-4.0%	-3.7%	0.3%
1Y	257.4%	15.2%	31.1%

Rendement vs Industrie: VERA a dépassé le secteur US Biotechs qui a rapporté 15.2 % au cours de l'année écoulée.

Rendement vs marché: VERA a dépassé le marché US qui a rapporté 31.1 % au cours de l'année écoulée.

Volatilité des prix

Is VERA's price volatile compared to industry and market?
VERA volatility
VERA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: VERA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de VERA ( 8% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2016	82	Marshall Fordyce	veratx.com

Vera Therapeutics, Inc. est une société de biotechnologie en phase clinique qui se concentre sur le développement et la commercialisation de traitements pour les patients atteints de maladies immunologiques graves. Son principal produit candidat est l'atacicept, une protéine de fusion auto-administrée par injection sous-cutanée, qui fait l'objet d'un essai clinique de phase III pour les patients atteints de néphropathie à immunoglobuline A, et d'un essai clinique de phase II pour le traitement de la néphrite lupique. Elle développe également MAU868, un anticorps monoclonal humain pour le traitement des infections par la virémie BK.

Vera Therapeutics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Vera Therapeutics se comparent-ils à sa capitalisation boursière ?
VERA statistiques fondamentales
Capitalisation boursière	US$2.90b
Bénéfices(TTM)	-US$134.38m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-22.2x

Ratio P/E

Le site VERA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
VERA compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$134.38m
Les revenus	-US$134.38m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-2.12
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	17.5%

Quelles ont été les performances à long terme de VERA?

Voir les performances historiques et les comparaisons

VERA Aperçu des actions

Récompenses

Analyse des risques

Vera Therapeutics, Inc. Concurrents

OTCPK:VSBC

US$3.1b

NasdaqGS:DYN

US$3.1b

NasdaqGS:AGIO

US$3.1b

NasdaqGM:XENE

US$3.0b

Historique des prix et performances

Nouvelles et mises à jour récentes

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Recent updates

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors